首页> 外文期刊>Transplantation Proceedings >Orthotopic liver transplantation in patients with portal vein thrombosis in the absence of hepatocellular carcinoma
【24h】

Orthotopic liver transplantation in patients with portal vein thrombosis in the absence of hepatocellular carcinoma

机译:没有肝细胞癌的门静脉血栓形成患者的原位肝移植

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Liver transplantation (OLT) in the setting of portal vein thrombosis (PVT) has been a matter of controversy in the past. We herein report our experience with OLT for PVT in the absence of hepatocellular carcinoma. Patients and Methods: Data from patients undergoing OLT for end-stage liver disease, having a documented PVT before OLT, were reviewed. Results: Twenty-five patients were included for the period July, 2003 to December, 2009. There were 20 men and 5 women of median age 57 years. Median values for waiting time and Model for End-Stage Liver Disease score were 150 days and 18, respectively. PVT was classified as grade II (n = 6), IIIa (n = 7), IIIb (n = 9), or IVa (n = 3). Partial portal vein resection/reconstruction, operative thrombectomy, and eversion thromboendovenectomy were performed in 2, 16, and 7 instances, respectively. After a median follow-up of 18 months, 14 patients are alive. Survival rates at 3, 6, 9, and 12, months and 3 years post-OLT were 68%, 64%, 61%, 61%, and 61%, respectively. PVT grade was a negative predictor of survival by Cox proportional hazard analysis (P =.0253). Conclusion: Despite the technical innovations in recent years, PVT grade correlated with poor patient survival irrespective of the surgical technique.
机译:背景:过去,在门静脉血栓形成(PVT)背景下进行肝移植(OLT)一直是一个有争议的问题。我们在此报告了在没有肝细胞癌的情况下OLT用于PVT的经验。患者和方法:回顾了接受OLT进行的终末期肝病患者的数据,并在OLT前记录了PVT。结果:2003年7月至2009年12月,共纳入25例患者。中位年龄57岁,男性20例,女性5例。等待时间和终末期肝病模型评分的中位数分别为150天和18。 PVT分为II级(n = 6),IIIa(n = 7),IIIb(n = 9)或IVa(n = 3)。分别在2、16和7例中进行了部分门静脉切除/重建,手术血栓切除术和外翻血栓内膜切除术。中位随访18个月后,有14名患者还活着。 OLT术后3、6、9和12月和3年的存活率分别为68%,64%,61%,61%和61%。通过Cox比例风险分析,PVT等级是生存的阴性预测指标(P = .0253)。结论:尽管近年来进行了技术创新,但无论采用何种外科手术技术,PVT评分均与患者生存不良相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号